Agents and Actions

, Volume 35, Issue 1–2, pp 71–78 | Cite as

Evidence that endogenous interleukin-1 is involved in leukocyte migration in acute experimental inflammation in rats and mice

  • M. Perretti
  • E. Solito
  • L. Parente
Inflammation and Immunomodulation


As a putative mediator of inflammation interleukin-1 has been implicated in the recruitment of leukocytes during the early stages of the inflammatory reaction. In the present report we have investigated the release of endogenous IL-1 in the rat zymosan pleurisy and in the mouse zymosan peritonitis. In both cases the release of the cytokine was maximal 4 hours after zymosan injection and appeared to be time-related to neutrophil migration into the inflammatory site. The effect ofin vivo treatment with dexamethasone in rat pleurisy and with polyclonal anti-murine IL-1β antibody in mouse peritonitis was also assessed. The steroid reduced both cell migration and the release of IL-1-like activity as well as the formation of exudate and the release of eicosanoids. The anti-IL-1β serum inhibited selectively the number of neutrophil that migrated to the inflamed site (∼40%) and the IL-1 activity recovered in (∼70%) the exudate.In vitro incubation of the inflammatory exudate with polyclonal anti-murine IL-1α or anti-murine IL-1β sera allowed the identification of the IL-1 species present. In the rat pleurisy IL-1 biological activity was mainly due to the α species, whereas IL-1β was the only species apparently present in the mouse peritoneal exudate.


Dexamethasone Peritonitis Eicosanoid Neutrophil Migration Leukocyte Migration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    H. Z. Movat,Tumor necrosis factor and interleukin-1: role in acute inflammation and microvascular injury. J. Lab. Clin. Med.110, 668–681 (1987).PubMedGoogle Scholar
  2. [2]
    M. Rampart and T. J. Williams,Evidence that neutrophil accumulation induced by interleukin-1 requires both local protein biosynthesis and neutrophil CD18 antigen expression in vivo. Br. J. Pharmacol.94, 1143–1148 (1988).PubMedGoogle Scholar
  3. [3]
    M. Rampart, W. Fiers, W. de Smet and A. G. Herman,Different pro-inflammatory profiles of interleukin-1 (IL-1) and tumor necrosis factor (TNF) in a in vivo model of inflammation. Agents Actions26, 186–188 (1989).PubMedGoogle Scholar
  4. [4]
    L. H. Faccioli, G. E. P. Souza, F. Q. Cunha, S. Poole and S. H. Ferreira,Recombinant interleukin-1 and tumor necrosis factor induce neutrophil migration “in vivo” by indirect mechanisms. Agents Actions30, 344–349 (1990).CrossRefPubMedGoogle Scholar
  5. [5]
    K. Paganelli-Parker, W. R. Benjamin, K. L. Kaffka and P. L. Kilian,Presence of IL-1 receptors on human and murine neutrophils. Relevance to IL-1-mediated effects in inflammation. J. Immunol.142, 537–542 (1989).PubMedGoogle Scholar
  6. [6]
    L. Borish, R. Rosenbaum, B. McDonald and L. Rosenwasser,Recombinant interleukin-1β interacts with high-affinity receptors to activate neutrophil leukotriene B 4 synthesis. Inflammation14, 151–162 (1990).CrossRefPubMedGoogle Scholar
  7. [7]
    J. S. Pober,Cytokine-mediated activation of vascular endothelium. Physiology and Pathology. Am. J. Pathol.133, 426–433 (1988).PubMedGoogle Scholar
  8. [8]
    M. B. Furie and D. D. McHugh,Migration of neutrophils across endothelial monolayers is stimulated by treatment of the monolayers with interleukin-1 or tumor necrosis factor. J. Immunol.143, 3309–3317 (1989).PubMedGoogle Scholar
  9. [9]
    K. Goto, S. Nakamura, F. Goto and M. Yoshinaga,Generation of an interleukin-1-like lymphocyte-stimulating factor at inflammatory sites: correlation with the infiltration of polymorphonuclear leukocytes. Br. J. exp. Path.65, 521–532 (1984).Google Scholar
  10. [10]
    G. Beck, G. S. Habicht, J. L. Benach and F. Miller,Interleukin-1: a common endogenous mediator of inflammation and the local Schwartzman reaction. J. Immunol.136, 3025–3031 (1986).PubMedGoogle Scholar
  11. [11]
    J. E. Gershenwald, Y. Fong, T. J. Fahey III, S. E. Calvano, R. Chizzonite, P. L. Kilian, S. F. Lowry and L. L. Moldawer,Interleukin 1 receptor blockade attenuates the host inflammatory response, Proc. Nat. Acad. Sci. (USA)87, 4966–4970 (1990).Google Scholar
  12. [12]
    L. Parente, M. S. Koh, D. A. Willoughby and A. Kitchen,Studies on cell motility in inflammation. I. The chemotactic activity of experimental, immunological and non-immunological, inflammatory exudates. Agents Actions9, 190–195 (1979).CrossRefPubMedGoogle Scholar
  13. [13]
    S. R. Lundy, R. L. Dowling, T. M. Stevens, J. S. Kerr, W. M. Mackin and K. R. Gans,Kinetics of phospholipase A 2,arachidonic acid, and eicosanoid appearance in mouse zymosan peritonitis. J. Immunol.144, 2671–2677 (1990).PubMedGoogle Scholar
  14. [14]
    J. Kaye, S. Porcelli, J. Tite, B. Jones and C. A. Janeway, Jr.,Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells. J. Exp. Med.158, 836–856 (1983).PubMedGoogle Scholar
  15. [15]
    T. Suda, P. Hodgkin, F. Lee and A. Zlotnik,Biological activity of recombinant murine interleukin-6 in interleukin-1 T cell assays. J. Immunol. Meth.120, 173–178 (1989).CrossRefGoogle Scholar
  16. [16]
    S. J. Hopkins and M. Humphreys,Simple, sensitive and specific bioassay of interleukin-1. J. Immunol. Meth.120, 271–276 (1989).CrossRefGoogle Scholar
  17. [17]
    O. H. Lowry, N. J. Rosebrough, A. Lewis Farr and R. J. Randall,Protein measurement with the folin phenol reagent. J. Biol. Chem.193, 265–275 (1951).PubMedGoogle Scholar
  18. [18]
    N. S. Doherty, P. Poubelle, P. Borgeat, T. H. Beaver, G. L. Westrich and N. L. Schrader,Intraperitoneal injection of zymosan in mice induces pain, inflammation and the synthesis of peptidoleukotrienes and prostaglandin E 2. Prostaglandins30, 769–789 (1985).CrossRefPubMedGoogle Scholar
  19. [19]
    J. P. Tarayre, A. Delhon, M. Aliaga, M. Barbara, F. Bruniquel, V. Caillol, L. Puech, N. Consul and J. Tisnè-Versailles,Pharmacological studies on zymosan inflammation in rats and mice. 2: zymosan-induced pleurisy in rats. Pharmacol. Res.21, 385–395 (1989).PubMedGoogle Scholar
  20. [20]
    T. J. Sayers, T. A. Wiltrout, C. A. Bull, A. C. Denn III, A. M. Pilaro and B. Lokesh,Effect of cytokines on polymorphonuclear neutrophil infiltration in the mouse. Prostaglandin- and leukotriene-independent induction of infiltration by IL-1 and tumor necrosis factor. J. Immunol.141, 1670–1677 (1988).PubMedGoogle Scholar
  21. [21]
    P. M. Simmons, J. A. Salmon and S. Moncada,The release of leukotriene B 4 during experimental inflammation. Biochem. Pharmacol.32, 1353–1359 (1983).CrossRefPubMedGoogle Scholar
  22. [22]
    M. J. Forrest, P. J. Jose and T. J. Williams,Kinetics of the generation and action of chemical mediators in zymosan-induced inflammation of the rabbit peritoneal cavity. Br. J. Pharmacol.89, 719–730 (1986).PubMedGoogle Scholar
  23. [23]
    S. Okusawa, C. A. Dinarello, K. B. Yancey, S. Endres, T. J. Lawley, M. M. Frank, J. F. Burke and J. A. Gelfand,C5a induction of human interleukin 1. Synergistic effect with endotoxin or interferon-γ. J. Immunol.139, 2935–2940 (1987).Google Scholar
  24. [24]
    M. Rola-Pleszczynski and I. Lemaire,Leukotrienes augment interleukin 1 production by human monocytes. J. Immunol.135, 3958–3961, 1985.PubMedGoogle Scholar
  25. [25]
    B. A. Parkar, M. E. McCormick and S. J. Foster,Leukotrienes do not regulate interleukin 1 production by activated macrophages. Biochem. Biophys. Res. Commun.169, 422–429 (1990).CrossRefPubMedGoogle Scholar
  26. [26]
    T. Yoshimura, K. Matsushima, J. J. Oppenheim and E. J. Leonard,Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL-1). J. Immunol.139, 788–793 (1987).PubMedGoogle Scholar
  27. [27]
    D. Westmacott, J. Wadsworth and D. P. Bloxham,Chemotactic activity of recombinant human interleucin-1. Agents Actions21, 323–324 (1987).CrossRefPubMedGoogle Scholar
  28. [28]
    C. G. Larsen, A. O. Anderson, J. J. Oppenheim and K. Matsushima,Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumor necrosis factor. Immunology68, 31–36 (1989).PubMedGoogle Scholar
  29. [29]
    P. D. Collins, P. J. Jose and T. J. Williams,The sequential generation of neutrophil chemoattractant proteins in acute inflammation in the rabbit in vivo. Relationship between C5a and proteins with the characteristics of IL-8/neutrophil-activating protein 1. J. Immunol.146, 677–684 (1991).PubMedGoogle Scholar
  30. [30]
    E. Solito and L. Parente,Modulation of phospholipase A 2,activity in human fibroblasts. Br. J. Pharmacol.96, 656–660 (1989).PubMedGoogle Scholar
  31. [31]
    J. L. Masferrer, B. S. Zweifel, K. Seibert and P. Needleman,Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest.86, 1375–1379 (1990).PubMedGoogle Scholar
  32. [32]
    M. Goppelt-Struebe, D. Wolter and K. Resch,Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A 2 but also at the level of cyclo-oxygenase/PGE isomerase. Br. J. Pharmacol.98, 1287–1295 (1989).PubMedGoogle Scholar
  33. [33]
    W. Lee, J. J. Oppenheim and K. Matsushima,Analysis of the suppression of IL-1α and IL-1β production in human peripheral blood mononuclear adherent cells by a glucocorticoid hormone.J. Immunol. 140, 1895–1902 (1988).PubMedGoogle Scholar
  34. [34]
    M. Perretti, C. Becherucci, G. Scapigliati and L. Parente,The effect of adrenalectomy on interleukin-1 release in vitro and in vivo. Br. J. Pharmacol.98, 1137–1142 (1989).PubMedGoogle Scholar
  35. [35]
    C. L. Czakowski, J. W. Coffey and K. P. Meyers,Treatment with recombinant IL-1 receptor antagonist (IL-1ra) suppressess the development of zymosan-induced pleurisy. FASEB J5, A634 (1991).Google Scholar
  36. [36]
    R. F. Kampshmidt and E. Franks,The physical and biological properties of rat interleukin-1. J. Leukocyte Biol.37, 715 (1985).Google Scholar
  37. [37]
    T. Nishida, N. Nishino, M. Takano, Y. Sekiguchi, K. Kaway, K. Mizuno, S. Nakai, Y. Masoi and Y. Hirai,Molecular cloning and expression of rat interleukin-1α cDNA. J. Biochem.105, 351–357 (1989).PubMedGoogle Scholar
  38. [38]
    H. U. Beuscher, C. Gunther and M. Rollinghoff,IL-1β is secreted by activated murine macrophages as biologically inactive precursor. J. Immunol.144, 2179–2183 (1990).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1992

Authors and Affiliations

  • M. Perretti
    • 1
  • E. Solito
    • 1
  • L. Parente
    • 1
  1. 1.Sclavo Research CentreLaboratory of PharmacologySienaItaly

Personalised recommendations